Trevi Therapeutics
TRVI
63 hedge funds and large institutions have $70.2M invested in Trevi Therapeutics in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 4 closing their positions.
200% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 4
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
15% more funds holding
Funds holding: 55 → 63 (+8)
5.79% more ownership
Funds ownership: 76.25% → 82.03% (+5.8%)
34% less capital invested
Capital invested by funds: $106M → $70.2M (-$35.9M)
50% less call options, than puts
Call options by funds: $2K | Put options by funds: $4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
Tejara Capital
London,
United Kingdom
|
+$1.65M |
| 2 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$1.38M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.26M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$757K |
| 5 |
Renaissance Technologies
New York
|
+$720K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$11.3M |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$260K |
| 3 |
TCOT
Trust Company of Toledo
Holland,
Ohio
|
-$122K |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$96.2K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$54.7K |
TRVI Hedge Fund Activity: Q4 2023 in Review
63 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q4 2023, worth a combined $70.2M — down 34% from $106M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new TRVI positions and 4 closed out — a net gain of 8 holders — while 26 added to existing stakes and 14 trimmed.
The largest buyer was Tejara Capital, adding an estimated $1.65M. The largest seller was Fairmount Funds Management, exiting entirely with an estimated $11.3M sold.
- 63 institutional investors held Trevi Therapeutics (TRVI) as of Q4 2023, up from 55 in Q3 2023.
- Funds reported $70.2M of Trevi Therapeutics stock for Q4 2023, down 34% quarter-over-quarter.
- 12 funds opened new Trevi Therapeutics positions in Q4 2023 and 4 closed out, a net change of +8 holders.
- The largest Trevi Therapeutics buyer in Q4 2023 was Tejara Capital, an estimated $1.65M added.
- The largest Trevi Therapeutics seller in Q4 2023 was Fairmount Funds Management, an estimated $11.3M sold.
Based on aggregated 13F filings for Q4 2023.